Jakafi has been approved by the FDA in acute GVHD since 2019 and has been on the US market since 2011 for myelofibrosis and also picked up an indication in polycythemia vera in 2014.

The company faces a critical period in 2025 as it prepares for the loss of exclusivity (LOE) of its key drug, Jakafi, in 2028. Although Incyte has several potential product launches and pivotal ...